Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis

References

• Taal M, Brenner B. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000; 57: 1803–17.
   PubMed Web of Science ®Google Scholar
• El Nahas A. Renal scarring: the role of angiotensin II. Nephrol Dial Transplant 1995; 10: 28–32.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997; 52: 1497–510.
   Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62.
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G, LocateIli F, Mann JF, Motolese M, et al. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Convert-ing-Enzyme Inhibition in Progressive Renal Insuffi-ciency Study Group. N Engl J Med 1996; 334: 939–45.
   Google Scholar
• Hollenberg N. Impact of angiotensin II on the kidney: does an angiotensin II receptor blocker make sense? Am J Kidney Dis 2000; 36: 18–23.
   Web of Science ®Google Scholar
• Schieppati A, Remuzzi G. The future of renoprotection: frustration and promises. Kidney Int 2003; 64: 1947–55.
   PubMed Web of Science ®Google Scholar
• Stomello M, Valvo E, Scapellato L. Angiotensin converting enzyme inhibition in normotensive type II diabetics with persistent proteinuria. J Hypertens Suppl 1989; 7: S314–S5.
   Google Scholar
• Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive type 1 diabetic patients irrespective of its hypotensive effect. Diabetologia 1990; 33: 470–6.
   PubMed Web of Science ®Google Scholar
• Tylicki L, Renke M, Rutkowski P. Rutkowski B. Short-term effects of angiotensin II receptor blockade in patients with primary glomerulonephritis-pilot study. J Ren Nutr 2002; 12: 122–5.
   Google Scholar
• Nielsen S, Dollerup J, Nielsen B, Jensen H, Mogensen C. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 (Suppl 2): S19–23.
   Google Scholar
• Haas M, Leko-Mohr Z, Erler C, Mayer G. Anti-proteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 2002; 40: 458–63.
   PubMed Web of Science ®Google Scholar
• Perico N, Remuzzi A, Sangalli F, et al. The antipro-teinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indometacin. J Am Soc Nephrol 1998; 9: 2308–17.
   PubMed Web of Science ®Google Scholar
• Andersen S, Tarnow L, Rossing P, Hansen B, Parving H. Renoprotective effects of angiotensin II receptor block-ade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601–6.
   Google Scholar
• Gansevoort R, De Zeeuw D, De Jong P. Is the anti-proteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861–7.
   PubMed Web of Science ®Google Scholar
• Mane M, Lievre M, Chatellier G, Mann J, Passa P. Menard J, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). Br Med J 2004; 328: 495.
   Google Scholar
• Taal M, Brenner B. Combination ACEI and ARB therapy: additional benefit in renoprotection. Curr Opin Nephrol Hypertens 2002; 11: 377–81.
   PubMed Web of Science ®Google Scholar
• Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18–25.
   PubMed Web of Science ®Google Scholar
• Russo D, Pisani A, Balletta M, et al. Additive antipro-teinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851–6.
   PubMed Web of Science ®Google Scholar
• Ferrari P, Marti H, Pfister M, Frey F. Additive anti-proteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002; 20: 125–30.
   PubMed Web of Science ®Google Scholar
• Laverman G, Navis G, Henning R, De Jong P. De Zeeuw Scand J Urol Nephrol 38 D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002; 62: 1020–5.
   Google Scholar
• Berger E, Bader B, Ebert C, Risler T, Erley C. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 2002; 20: 739–43.
   Google Scholar
• Campbel R, Sangalli F, Perticuccu E, Perticucci E, Aros C, Viscarra C, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63: 1094–103.
   PubMed Web of Science ®Google Scholar
• Luno J, Barrio V, Goicoechea M, Gonzalez C, De Vinuesa S. Gomez F, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2002; 62 (Suppl 82): 47–52.
   Google Scholar
• Mogensen C, Neldam S. Tikkanene I, Oren S. Viskoper R, Watts R, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin depen-dent diabetes: the candesartan and lisinopril microalbu-minuria (CALM) study. Br Med J 2000; 321: 1440–4.
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Rossing P, Jensen B, Parving H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63: 1874–80.
   Google Scholar
• Rossing K, Christensen P, Jensen B, Parving H. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabetes Care 2002; 25: 95–100.
   PubMed Web of Science ®Google Scholar
• Kincaid-Smith P. Fairley K, Packha D. Randomized controlled crossover study of the effect on protein- uria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002; 17: 597–601.
   Google Scholar
• Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE):a randomised controlled trial. Lancet 2003; 361: 117–24.
   PubMed Web of Science ®Google Scholar
• Rutkowski P. Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B. Low-dose dual blockade of the renin-angiotensin system in patients with primaryglomerulonephritis. Am J Kidney Dis 2004; 43: 260–8.
   Google Scholar
• Veelken R, Hilgers K, Mann J. The acute renal effects of angiotensin II receptor blockers. Nephrol Dial Transplant 1998; 13: 1928–9.
   Google Scholar
• Edwards R. Response of isolated renal arterioles to acetylcholine, dopamine and bradykinin. Am J Physiol 1985; 248: 181–9.
   Google Scholar
• Edwards R, Trizna W, Stack E, Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 1996; 276: 125–9.
   PubMed Web of Science ®Google Scholar